- Lonza to acquire Synaffix B.V., an innovative biotech company focused on antibody-drug conjugates (ADCs)
- Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
- Lonza and Synaffix will continue to expand their Center of Excellence for bioconjugate technology development, with a focus on out-licensing bioconjugates technologies for cytotoxic ADCs, targeted gene therapy, immune cell engagers applications and beyond
- The acquisition comprises an initial financial consideration of €100 million in cash and up to €60 million in additional performance-based consideration
Basel, Switzerland, and Amsterdam, Netherlands, 1 June 2023 – Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, today announced it has acquired Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage technology platform for the development of ADCs. Synaffix revenues and margins will be recognized within the Lonza business from the date of acquisition.